These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21192453)

  • 1. [Rivastigmine patch effective for 24 hours. Effective dose, good tolerance, reliable therapeutic effectiveness].
    Burian R
    MMW Fortschr Med; 2010 Sep; 152(37):40-1. PubMed ID: 21192453
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials.
    Sadowsky CH; Farlow MR; Meng X; Olin JT
    Int J Clin Pract; 2010 Jan; 64(2):188-93. PubMed ID: 20089009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
    Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
    Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivastigmine patches: line extension. No therapeutic advantage and less convenient than capsules.
    Prescrire Int; 2009 Feb; 18(99):19. PubMed ID: 19391277
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.
    Darreh-Shori T; Jelic V
    Expert Opin Drug Saf; 2010 Jan; 9(1):167-76. PubMed ID: 20021294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rivastigmine patch for dementia.
    Med Lett Drugs Ther; 2008 Mar; 50(1282):21-2. PubMed ID: 18356801
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.
    Lefèvre G; Sedek G; Jhee SS; Leibowitz MT; Huang HL; Enz A; Maton S; Ereshefsky L; Pommier F; Schmidli H; Appel-Dingemanse S
    Clin Pharmacol Ther; 2008 Jan; 83(1):106-14. PubMed ID: 17522596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia].
    Schmidt R; Alf C; Bancher C; Benke T; Berek K; Dal-Bianco P; Führwürth G; Imarhiagbe D; Jagsch C; Lechner A; Rainer M; Reisecker F; Rotaru J; Uranüs M; Walter A; Winkler A; Wuschitz A
    Neuropsychiatr; 2009; 23(1):58-63. PubMed ID: 19272293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
    Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R
    Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maculopapular eruption to rivastigmine's transdermal patch application and successful oral desensitization.
    Makris M; Koulouris S; Koti I; Aggelides X; Kalogeromitros D
    Allergy; 2010 Jul; 65(7):925-6. PubMed ID: 19889118
    [No Abstract]   [Full Text] [Related]  

  • 11. High-dose cholinergic therapy with rivastigmine patch does not prolong QTc time in patients with Alzheimer's disease.
    Riepe MW
    J Clin Psychiatry; 2014 Mar; 75(3):288. PubMed ID: 24717382
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetic rationale for the rivastigmine patch.
    Cummings J; Lefèvre G; Small G; Appel-Dingemanse S
    Neurology; 2007 Jul; 69(4 Suppl 1):S10-3. PubMed ID: 17646618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute dystonic reaction with rivastigmine.
    Dhikav V; Anand KS
    Int Psychogeriatr; 2013 Aug; 25(8):1385-6. PubMed ID: 23561545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low dose, high dose, or no dose: better prescribing of cholinesterase inhibitors for Alzheimer's disease.
    Ritchie CW; Zhinchin G
    Int Psychogeriatr; 2013 Apr; 25(4):511-5. PubMed ID: 23422014
    [No Abstract]   [Full Text] [Related]  

  • 15. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
    Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease.
    Winblad B; Kawata AK; Beusterien KM; Thomas SK; Wimo A; Lane R; Fillit H; Blesa R
    Int J Geriatr Psychiatry; 2007 May; 22(5):485-91. PubMed ID: 17407176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease.
    Blesa González R; Boada Rovira M; Martínez Parra C; Gil-Saladié D; Almagro CA; Gobartt Vázquez AL;
    Neurologia; 2011 Jun; 26(5):262-71. PubMed ID: 21227548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
    Farlow MR; Alva G; Meng X; Olin JT
    Curr Med Res Opin; 2010 Feb; 26(2):263-9. PubMed ID: 19929593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A transdermal patch of rivastigmine (Exelon)].
    Salmon E
    Rev Med Liege; 2008 Sep; 63(9):570-1. PubMed ID: 19051514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A comparative study of the effectiveness and tolerability of a procedure involving slow dose-escalation of rivastigmine in patients with mild or moderate Alzheimer-type dementia: the SCALEX study].
    Agüera-Ortiz LF; Ramos-García M; Gobartt AL;
    Rev Neurol; 2008 May 1-15; 46(9):517-24. PubMed ID: 18446692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.